A team of patent litigators assisting pharmaceutical company Teva successfully revoked Bayer’s patent in a Patents Court decision handed down on 8 October. The case revolved around the issue of obviousness of the compound of a tosylate, of active ingredient sorafenib (a cancer drug known as Nexavar).

You can read a quick report on the case written by Claire Phipps-Jones, who draws similitudes with Hospira v Genentech.

Online magazine Juve Patent also published an article on the Court victory, looking at the ongoing parallel litigation in other jurisdictions.

The patent litigation team assisting Teva on this case includes partners Rob Burrows, Rachel Mumby and associate Emma Irwin.